Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -47,047 | -35,080 | -23,860 | -11,489 | -41,066 |
| Depreciation Amortization | 37 | 27 | 18 | 9 | 33 |
| Other Working Capital | 2,284 | 1,958 | 845 | -2,305 | 4,678 |
| Other Operating Activity | 2,959 | 4,119 | 2,559 | 1,680 | 3,390 |
| Operating Cash Flow | $-41,767 | $-28,976 | $-20,438 | $-12,105 | $-32,965 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 30,000 | 30,000 | 20,000 | 10,000 | 30,000 |
| Common Stock Issued | 1,227 | 376 | 376 | N/A | 10,033 |
| Financing Cash Flow | $31,227 | $30,376 | $20,376 | $10,000 | $40,033 |
| Beginning Cash Position | 25,660 | 25,660 | 25,660 | 25,660 | 18,592 |
| End Cash Position | 15,120 | 27,060 | 25,598 | 23,555 | 25,660 |
| Net Cash Flow | $-10,540 | $1,400 | $-62 | $-2,105 | $7,068 |
| Free Cash Flow | |||||
| Operating Cash Flow | -41,767 | -28,976 | -20,438 | -12,105 | -32,965 |
| Free Cash Flow | -41,767 | -28,976 | -20,438 | -12,105 | -32,965 |